Why Are the American People Seeing More FDA COVID Vaccine Approvals Instead of Accountability for Growing Cases of COVID Vaccine Harm?

By The Blog Source

Moderna's new low-dose COVID-19 vaccination was approved by the FDA on Friday, but its usage is restricted to older adults and anyone who poses health hazards. For Americans 65 and over, as well as those 12 to 64 with at least one high-risk medical condition, the FDA approved mNexspike.

The recently licensed vaccine offers a possible step toward next-generation COVID vaccines because it uses a revised immunological target and only needs a fifth of the dose of Spikevax. According to corporate data, mNexspike was found to be safe and as effective as Moderna's existing vaccination in a clinical trial involving over 11,000 individuals.

A new low-dose COVID-19 vaccine from Moderna was allegedly approved by the Food and Drug Administration late Friday, but its usage was limited to certain high-risk populations. The new vaccine, called mNexspike, is intended for adults 65 and older and those between the ages of 12 and 64 who have underlying medical disorders that increase their chance of developing a serious virus-related illness.

In a statement issued on Saturday, Moderna CEO Stephane Bancel praised the action as a significant step that "adds an important new tool to help protect people at high risk of severe disease."

The recently approved mNexspike has a far smaller scope than Moderna's current Spikevax shot, which is available for almost all age groups six months and older. Only one-fifth of the dose required for the original Spikevax is required because the vaccine's recipe uses an improved immunological target. The goal of the change is to lessen the dosage load while maintaining protection.

Based on clinical data from a trial with about 11,400 participants aged 12 and up, the FDA approved the product. According to Moderna, the findings demonstrated that mNexspike complied with safety regulations and offered immune protection comparable to or, in certain cases, superior to Spikevax.

Compared to earlier vaccination authorizations, which were used more widely, the decision to restrict the use of mNexspike represents a substantial shift. This change coincides with the Trump administration's health officials, including Health and Human Services Secretary Robert F. Kennedy Jr., taking a more cautious stance on COVID-19 immunizations.

To join the Diamond and Silk Monthly Supporter Program, visit http://SupportDiamondandSilk.com.
Lindell TV, VOCL, ChatDit, Rumble, TruthSocial, and Diamond and Silk Media are all excellent ways to stay connected with Diamond and Silk.